EZH2 and metastatic prostate carcinoma: Expression-microarray studies have also identified EZH2 as a gene overexpressed in hormone-refractory metastatic prostate cancer: notably, patients with clinically localised prostate cancer (Varambally et al, 2002) that express EZH2 have a worse prognosis than those that do not express the protein.